{"id":"NCT00577655","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Albuterol HFA MDI in Pediatric Participants With Asthma","officialTitle":"Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2007-12-20","resultsPosted":"2009-12-03","lastUpdate":"2021-11-12"},"enrollment":103,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Albuterol","otherNames":["ProAir® HFA","Albuterol Sulfate"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Proventil® HFA","otherNames":["albuterol sulfate"]}],"arms":[{"label":"Albuterol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.","primaryOutcome":{"measure":"Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22","timeFrame":"35±5 and 10±2 min prior to dosing, and at 5±2, 15±5, 30±5, 45±5, 60±10, 120 ±10 post dosing on Day 22 or last observation","effectByArm":[{"arm":"Albuterol","deltaMin":12.849,"sd":1.005},{"arm":"Placebo","deltaMin":9.353,"sd":1.017}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0138"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Headache","Nasopharyngitis"]}}